Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria :~* Participants with type-2 diabetes mellitus (T2DM) for at least 3 months before the screening visit.~* On diet/exercise and/or treatment with metformin (stable dose of ≥1500 mg/day or maximal tolerated dose) for at least 3 months prior to screening.~* Signed informed consent.~Exclusion criteria:~* At screening, participant's age \< legal age of adulthood and \>80 years.~* Glycated hemoglobin at screening visit \<7.0% or \>10.0%.~* Body mass index (BMI) \<25 kg/m\^2 or \>45.0 kg/m\^2.~* Pregnant or lactating women.~* Women of childbearing potential (WOCBP) not protected by highly-effective method(s) of birth control and/or who are unwilling or unable to be tested for pregnancy.~* Diagnosis of type 1 diabetes mellitus.~* Fasting plasma glucose of \>15 mmol/L (270 mg/dL) measured by the central laboratory at screening (Visit 1), and confirmed (\>15 mmol/L \[270 mg/dL\]) by a repeat test before randomization.~* Treatment with glucose-lowering agents(s) other than metformin, currently or within the 3 months prior to screening.~* Previous insulin use, except for episode(s) of short-term treatment (≤15 consecutive days) for intercurrent illness or pregnancy, or use of insulin within the last 6 months.~* Contraindication(s) to metformin use.~* Contraindication(s) to liraglutide use.~* Significant change in body weight in the 3 months before screening.~* Poorly controlled hypertension (a resting systolic blood pressure (SBP) \>160 mm Hg and/or diastolic blood pressure (DBP) \>95 mm Hg at screening).~* History of long QT syndrome and/or QTc more than 450 ms at screening visit.~* History of pancreatitis or pancreatectomy.~* History of weight loss surgery.~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC.~* Any prior exposure to drugs belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists/GLP-1 analogs.~* Contraindications or known hypersensitivity reaction to glucagon.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for SAR425899) subcutaneous (SC) injection once daily (QD) from Week 1 to Week 26, matching 3 SAR425899 dose levels of 0.12 mg, 0.16 mg and 0.20 mg.
- SAR425899 0.12 mg (Type: EXPERIMENTAL): SAR425899 SC injection QD at maintenance dose of 0.12 mg for 25 weeks (Week 2 to Week 26) following 1 week dose increase step (0.06 mg at Week 1).
- SAR425899 0.16 mg (Type: EXPERIMENTAL): SAR425899 SC injection QD at maintenance dose of 0.16 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase step (0.06 mg at Week 1 and 0.12 mg at Week 2).
- SAR425899 0.20 mg (Type: EXPERIMENTAL): SAR425899 SC injection QD at maintenance dose of 0.20 mg for 23 weeks (Week 4 to Week 26) following 3 weeks dose increase step (0.06 mg at Week 1, 0.12 mg at Week 2 and 0.16 mg at Week 3).
- Liraglutide (Type: ACTIVE_COMPARATOR): Liraglutide SC injection QD at maintenance dose of 1.8 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase steps (0.6 mg daily at Week 1 and by 1.2 mg daily at Week 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).